Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
3 Apr 24
DEFA14A
Additional proxy soliciting materials
3 Apr 24
DEF 14A
Definitive proxy
3 Apr 24
8-K
Entry into a Material Definitive Agreement
3 Apr 24
8-K
Departure of Directors or Certain Officers
26 Mar 24
10-K
2023 FY
Annual report
7 Mar 24
8-K
Harvard Bioscience Announces Fourth Quarter 2023 Financial Results
7 Mar 24
8-K
Results of Operations and Financial Condition
5 Jan 24
10-Q
2023 Q3
Quarterly report
7 Nov 23
8-K
Harvard Bioscience Announces Third Quarter 2023 Financial Results
7 Nov 23
UPLOAD
Letter from SEC
16 Aug 23
CORRESP
Correspondence with SEC
9 Aug 23
10-Q
2023 Q2
Quarterly report
8 Aug 23
8-K
Harvard Bioscience Announces Second Quarter 2023 Financial Results
8 Aug 23
UPLOAD
Letter from SEC
28 Jul 23
8-K
Harvard Bioscience Appoints Jennifer Cote as Chief Financial Officer
20 Jun 23
SD
Conflict minerals disclosure
30 May 23
8-K
Submission of Matters to a Vote of Security Holders
15 May 23
10-Q
2023 Q1
Quarterly report
26 Apr 23
8-K
Harvard Bioscience Announces First Quarter 2023 Financial Results
25 Apr 23
ARS
2022 FY
Annual report to shareholders
7 Apr 23
DEF 14A
Definitive proxy
5 Apr 23
8-K
Other Events
13 Mar 23
8-K
Departure of Directors or Certain Officers
10 Mar 23
10-K
2022 FY
Annual report
9 Mar 23
8-K
Harvard Bioscience Announces Fourth Quarter 2022 Financial Results
9 Mar 23
8-K
Departure of Directors or Certain Officers
19 Jan 23
8-K/A
Departure of Directors or Certain Officers
3 Jan 23
8-K
Harvard Bioscience Announces CFO Transition
12 Dec 22
10-Q
2022 Q3
Quarterly report
8 Nov 22
8-K
Harvard Bioscience Announces Third Quarter 2022 Financial Results
8 Nov 22
10-Q
2022 Q2
Quarterly report
4 Aug 22
8-K
Harvard Bioscience Announces Second Quarter 2022 Financial Results
4 Aug 22
S-8
Registration of securities for employees
8 Jun 22
SD
Conflict minerals disclosure
20 May 22
8-K
Departure of Directors or Certain Officers
17 May 22
10-Q
2022 Q1
Quarterly report
4 May 22
8-K
Harvard Bioscience Announces First Quarter 2022 Financial Results
4 May 22
8-K
Entry into a Material Definitive Agreement
28 Apr 22
DEF 14A
Definitive proxy
7 Apr 22
Latest ownership filings
SC 13G
Leviticus Partners LP
19 Mar 24
4
Jennifer Cote
7 Mar 24
4
James W Green
7 Mar 24
SC 13G/A
Harvey Partners, LLC
14 Feb 24
SC 13G/A
PUNCH & ASSOCIATES INVESTMENT MANAGEMENT, INC.
14 Feb 24
SC 13G/A
B. Riley Asset Management, LLC
14 Feb 24
SC 13G/A
Harvard Apparatus Regenerative Technology, Inc.
13 Feb 24
SC 13G/A
Leviticus Partners LP
22 Jan 24
4
James W Green
3 Jan 24
4
Jennifer Cote
3 Jan 24
SC 13G
Leviticus Partners LP
28 Aug 23
4
James W Green
21 Aug 23
4
James W Green
13 Jun 23
4
ALAN I EDRICK
23 May 23
4
Katherine A. Eade
23 May 23
4
Thomas W Loewald
23 May 23
4
BERTRAND LOY
23 May 23
4
ALAN I EDRICK
16 Mar 23
4
James W Green
15 Mar 23
4
James W Green
8 Mar 23
4
Jennifer Cote
8 Mar 23
SC 13G/A
B. Riley Asset Management, LLC
16 Feb 23
SC 13G
B. Riley Asset Management, LLC
15 Feb 23
SC 13G
Harvey Partners, LLC
14 Feb 23
SC 13G/A
PUNCH & ASSOCIATES INVESTMENT MANAGEMENT, INC.
13 Feb 23
SC 13G/A
Portolan Capital Management, LLC
13 Feb 23
SC 13G/A
Leviticus Partners LP
11 Jan 23
3
Jennifer Cote
3 Jan 23
4
Michael A. Rossi
3 Jan 23
4
James W Green
3 Jan 23
SC 13G
Leviticus Partners LP
21 Dec 22
4
James W Green
2 Dec 22
4
BERTRAND LOY
15 Sep 22
4
BERTRAND LOY
29 Aug 22
4
BERTRAND LOY
26 Aug 22
4
BERTRAND LOY
24 Aug 22
4
BERTRAND LOY
22 Aug 22
4
James W Green
18 Aug 22
4
Michael A. Rossi
20 Jul 22
4
James W Green
12 Jul 22